How Artrya’s Salix Platform Is Transforming Cardiac Care at Cone Health
Artrya Limited has signed a significant five-year commercial agreement with Cone Health, marking its third U.S. customer and solidifying its foothold in the American healthcare market with its AI-powered Salix platform.
- Five-year commercial agreement with Cone Health valued at minimum US$0.45M
- Salix AI platform to be integrated across Cone Health’s hospital network
- All three U.S. foundation partners converted to commercial customers in 2025
- Revenue model includes fixed monthly SaaS fees plus fee-per-scan payments
- Onboarding supported by Artrya’s new U.S.-based Customer Success team
Artrya’s U.S. Commercial Momentum
Artrya Limited, an Australian medical technology company, has taken a decisive step forward in its U.S. expansion by securing a five-year commercial agreement with Cone Health, a leading healthcare network in North Carolina. This deal marks Artrya’s third U.S. commercial customer and completes the conversion of all its foundation partners into paying clients within 2025, underscoring the growing acceptance of its Salix AI-powered platform for coronary artery disease assessment.
The Salix Platform and Revenue Model
The agreement with Cone Health involves licensing the Salix Coronary Anatomy platform on a Software-as-a-Service (SaaS) basis, with a fixed monthly subscription fee over five years, valued at a minimum of US$0.45 million. Additionally, Artrya will generate fee-per-scan revenue from the Salix Coronary Plaque module, which benefits from U.S. reimbursement under a Category 1 CPT code. This dual revenue stream model reflects a mature commercial approach, combining predictable subscription income with scalable usage-based fees.
Integration and Clinical Impact
Cone Health plans to fully integrate the Salix platform across its network, which includes five hospitals, multiple ambulatory and urgent care centers, and over 120 physician practices. The platform’s ability to deliver near real-time, point-of-care analysis of coronary CT angiograms promises to enhance diagnostic accuracy and speed, potentially improving patient outcomes. Clinical leaders at Cone Health have praised the technology’s capacity to streamline workflows and reduce variability in cardiac imaging interpretation.
Supporting U.S. Operations
Artrya’s recently established Customer Success team based in Atlanta, Georgia, will lead the onboarding and ongoing support for Cone Health. This localized presence is a strategic move to ensure seamless integration, training, and customer service, which are critical factors in scaling adoption within complex healthcare systems.
Looking Ahead
With all three U.S. foundation partners now commercial customers, Artrya is positioned to accelerate growth in the American market throughout 2026. The company’s focus will likely be on expanding usage within existing customers and pursuing new partnerships, leveraging the clinical validation and reimbursement pathways established to date.
Bottom Line?
Artrya’s solidifying U.S. presence signals a promising growth trajectory, but execution in scaling adoption will be key to unlocking its full commercial potential.
Questions in the middle?
- How quickly will Artrya expand beyond its three foundation partners in the U.S.?
- What impact will reimbursement developments have on the adoption of the Salix Plaque module?
- Can Artrya’s Customer Success team maintain high integration standards as the customer base grows?
